Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria

Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of Plasmodium vivax malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayence, Annie, Vanden Eynde, Jean Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789594/
https://www.ncbi.nlm.nih.gov/pubmed/31366060
http://dx.doi.org/10.3390/ph12030115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789594/
https://www.ncbi.nlm.nih.gov/pubmed/31366060
http://dx.doi.org/10.3390/ph12030115

Ejemplares similares